Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma

Por Tsao, Hensin, Goel, Vikas, Wu, Heng, Yang, Guang, Haluska, Frank G.
Publicado em 2004

Loss of ARF sensitizes transgenic BRAF(V600E) mice to UV-induced melanoma via suppression of XPC

Por Luo, Chi, Sheng, Jinghao, Hu, Miaofen G., Haluska, Frank G., Cui, Rutao, Xu, Zhengping, Tsichlis, Philip N., Hu, Guo-fu, Hinds, Philip W.
Publicado em 2013

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

Por Pearson, Andrew D.J., Federico, Sara M., Aerts, Isabelle, Hargrave, Darren R., DuBois, Steven G., Iannone, Robert, Geschwindt, Ryan D., Wang, Ruixue, Haluska, Frank G., Trippett, Tanya M., Geoerger, Birgit
Publicado no Oncotarget (2016)

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

Por Sonnichsen, Daryl, Dorer, David J., Cortes, Jorge, Talpaz, Moshe, Deininger, Michael W., Shah, Neil P., Kantarjian, Hagop M., Bixby, Dale, Mauro, Michael J., Flinn, Ian W., Litwin, Jeffrey, Turner, Christopher D., Haluska, Frank G.
Publicado em 2013

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

Por Shah, Neil P., Talpaz, Moshe, Deininger, Michael W. N., Mauro, Michael J., Flinn, Ian W., Bixby, Dale, Lustgarten, Stephanie, Gozgit, Joseph M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Kantarjian, Hagop, Cortes, Jorge E.
Publicado em 2013

Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With...

Por Flaherty, Lawrence E., Othus, Megan, Atkins, Michael B., Tuthill, Ralph J., Thompson, John A., Vetto, John T., Haluska, Frank G., Pappo, Alberto S., Sosman, Jeffrey A., Redman, Bruce G., Moon, James, Ribas, Antoni, Kirkwood, John M., Sondak, Vernon K.
Publicado no J Clin Oncol (2014)

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Por Hodi, F. Stephen, Mihm, Martin C., Soiffer, Robert J., Haluska, Frank G., Butler, Marcus, Seiden, Michael V., Davis, Thomas, Henry-Spires, Rochele, MacRae, Suzanne, Willman, Ann, Padera, Robert, Jaklitsch, Michael T., Shankar, Sridhar, Chen, Teresa C., Korman, Alan, Allison, James P., Dranoff, Glenn
Publicado em 2003

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Por Cortes, Jorge E., Kantarjian, Hagop, Shah, Neil P., Bixby, Dale, Mauro, Michael J., Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I., Rivera, Victor M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Druker, Brian J., Deininger, Michael W.N., Talpaz, Moshe
Publicado em 2012

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

Por Hodi, F. Stephen, Butler, Marcus, Oble, Darryl A., Seiden, Michael V., Haluska, Frank G., Kruse, Andrea, MacRae, Suzanne, Nelson, Marybeth, Canning, Christine, Lowy, Israel, Korman, Alan, Lautz, David, Russell, Sara, Jaklitsch, Michael T., Ramaiya, Nikhil, Chen, Teresa C., Neuberg, Donna, Allison, James P., Mihm, Martin C., Dranoff, Glenn
Publicado em 2008

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Por Deininger, Michael W., Hodgson, J. Graeme, Shah, Neil P., Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E., Talpaz, Moshe, Baccarani, Michele, Müller, Martin C., Li, Jin, Parker, Wendy T., Lustgarten, Stephanie, Clackson, Tim, Haluska, Frank G., Guilhot, Francois, Kantarjian, Hagop M., Soverini, Simona, Hochhaus, Andreas, Hughes, Timothy P., Rivera, Victor M., Branford, Susan
Publicado no Blood (2016)